LENSAR (LNSR) Competitors $7.70 +0.20 (+2.67%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LNSR vs. RCEL, CVRX, SMTI, ZYXI, LUNG, ELMD, CATX, PROF, DRTS, and KRMDShould you be buying LENSAR stock or one of its competitors? The main competitors of LENSAR include AVITA Medical (RCEL), CVRx (CVRX), Sanara MedTech (SMTI), Zynex (ZYXI), Pulmonx (LUNG), Electromed (ELMD), Perspective Therapeutics (CATX), Profound Medical (PROF), Alpha Tau Medical (DRTS), and KORU Medical Systems (KRMD). These companies are all part of the "medical equipment" industry. LENSAR vs. AVITA Medical CVRx Sanara MedTech Zynex Pulmonx Electromed Perspective Therapeutics Profound Medical Alpha Tau Medical KORU Medical Systems AVITA Medical (NASDAQ:RCEL) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Do analysts recommend RCEL or LNSR? AVITA Medical presently has a consensus target price of $16.50, indicating a potential upside of 40.19%. LENSAR has a consensus target price of $8.00, indicating a potential upside of 3.90%. Given AVITA Medical's higher probable upside, analysts clearly believe AVITA Medical is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AVITA Medical 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33LENSAR 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in RCEL or LNSR? 27.7% of AVITA Medical shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 1.8% of AVITA Medical shares are held by company insiders. Comparatively, 66.0% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, RCEL or LNSR? AVITA Medical has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Does the MarketBeat Community favor RCEL or LNSR? AVITA Medical received 69 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 67.89% of users gave AVITA Medical an outperform vote while only 38.46% of users gave LENSAR an outperform vote. CompanyUnderperformOutperformAVITA MedicalOutperform Votes7467.89% Underperform Votes3532.11% LENSAROutperform Votes538.46% Underperform Votes861.54% Does the media prefer RCEL or LNSR? In the previous week, AVITA Medical had 3 more articles in the media than LENSAR. MarketBeat recorded 4 mentions for AVITA Medical and 1 mentions for LENSAR. AVITA Medical's average media sentiment score of 0.25 beat LENSAR's score of 0.00 indicating that AVITA Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AVITA Medical 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is RCEL or LNSR more profitable? LENSAR has a net margin of -34.03% compared to AVITA Medical's net margin of -95.47%. LENSAR's return on equity of -49.02% beat AVITA Medical's return on equity.Company Net Margins Return on Equity Return on Assets AVITA Medical-95.47% -194.69% -60.67% LENSAR -34.03%-49.02%-21.12% Which has higher earnings & valuation, RCEL or LNSR? LENSAR has lower revenue, but higher earnings than AVITA Medical. AVITA Medical is trading at a lower price-to-earnings ratio than LENSAR, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAVITA Medical$60.04M5.14-$35.38M-$2.23-5.28LENSAR$48.87M1.83-$14.38M-$1.46-5.27 SummaryLENSAR beats AVITA Medical on 9 of the 17 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get LENSAR News Delivered to You Automatically Sign up to receive the latest news and ratings for LNSR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LNSR vs. The Competition Export to ExcelMetricLENSARSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$89.44M$4.34B$5.12B$9.07BDividend YieldN/A41.46%4.91%4.22%P/E Ratio-5.2725.3791.3417.19Price / Sales1.8345.681,116.59116.80Price / CashN/A43.4542.6437.86Price / Book2.597.364.794.78Net Income-$14.38M$13.64M$120.07M$225.60M7 Day Performance1.99%-2.80%-1.89%-1.24%1 Month Performance3.49%0.56%11.45%3.36%1 Year Performance174.02%41.87%30.61%16.58% LENSAR Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LNSRLENSAR0.569 of 5 stars$7.70+2.7%$8.00+3.9%+191.7%$89.44M$48.87M-5.27110News CoverageRCELAVITA Medical1.6504 of 5 stars$12.49+2.3%$16.50+32.1%-5.3%$327.49M$50.14M-5.48130News CoveragePositive NewsCVRXCVRx3.7816 of 5 stars$13.21+3.0%$16.67+26.2%-49.2%$320.53M$47.26M-4.75200Positive NewsSMTISanara MedTech1.9969 of 5 stars$33.51-3.3%$44.00+31.3%-14.5%$292.88M$64.99M-35.0060ZYXIZynex3.4977 of 5 stars$8.42+3.4%$14.00+66.3%-21.1%$268.18M$184.32M54.271,100Positive NewsLUNGPulmonx2.6733 of 5 stars$6.12+0.3%$12.75+108.3%-49.2%$241.67M$79.30M-4.15250ELMDElectromedN/A$28.29+0.4%N/A+158.0%$239.28M$57.06M39.14174CATXPerspective Therapeutics3.3599 of 5 stars$3.49+0.3%$15.14+333.9%N/A$235.88M$1.43M0.00116Positive NewsPROFProfound Medical2.5362 of 5 stars$7.27-1.8%$13.75+89.1%-12.8%$218.32M$7.20M-5.52150High Trading VolumeDRTSAlpha Tau Medical1.9713 of 5 stars$3.09+0.7%$8.00+158.9%+10.3%$216.07MN/A-7.1480KRMDKORU Medical Systems1.3182 of 5 stars$4.29-0.2%$4.13-3.8%+74.0%$196.65M$28.52M-17.2080 Related Companies and Tools Related Companies AVITA Medical Competitors CVRx Competitors Sanara MedTech Competitors Zynex Competitors Pulmonx Competitors Electromed Competitors Perspective Therapeutics Competitors Profound Medical Competitors Alpha Tau Medical Competitors KORU Medical Systems Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LNSR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENSAR With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
